Author/Authors :
Saki, Nasrin Molecular Dermatology Research Center - Shiraz University of Medical Sciences, Shiraz, Iran , Heiran, Alireza Student research committee - Medical School - Shiraz University of Medical Sciences, Shiraz, Iran , Sheikhi Ghayur, Elham Molecular Dermatology Research Center - Shiraz University of Medical Sciences, Shiraz, Iran
Abstract :
Vitiligo is a pigmentation disorder involving 1% of the population. One of the first line depigmenting agents is monobenzyl ether of hydroquinone (MBEH). Repigmentation following sun exposure; however, can occur after successful treatment with MBEH. This study describes a 54-year-old gentleman who presented with a 7-year history of hyperpigmented lesions on his face following depigmentation therapy with MBEH. The patient was successfully treated with intralesional injections of tranexamic acid.
